These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15134554)

  • 1. Antiviral profile of HIV inhibitors in macrophages: implications for therapy.
    Perno CF; Balestra E; Francesconi M; Abdelahad D; Caliò R; Balzarini J; Aquaro S
    Curr Top Med Chem; 2004; 4(9):1009-15. PubMed ID: 15134554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies towards HIV-1 infection in macrophages.
    Perno CF; Svicher V; Schols D; Pollicita M; Balzarini J; Aquaro S
    Antiviral Res; 2006 Sep; 71(2-3):293-300. PubMed ID: 16806514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.
    Aquaro S; Caliò R; Balzarini J; Bellocchi MC; Garaci E; Perno CF
    Antiviral Res; 2002 Aug; 55(2):209-25. PubMed ID: 12103427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
    Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF
    J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.
    Aquaro S; Perno CF; Balestra E; Balzarini J; Cenci A; Francesconi M; Panti S; Serra F; Villani N; Caliò R
    J Leukoc Biol; 1997 Jul; 62(1):138-43. PubMed ID: 9226005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
    Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
    Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission.
    Van Herrewege Y; Penne L; Vereecken C; Fransen K; van der Groen G; Kestens L; Balzarini J; Vanham G
    AIDS Res Hum Retroviruses; 2002 Oct; 18(15):1091-102. PubMed ID: 12396448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The compound 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid inhibits HIV-1 replication by targeting the enzyme reverse transcriptase.
    Souza TM; Cirne-Santos CC; Rodrigues DQ; Abreu CM; Tanuri A; Ferreira VF; Marques IP; de Souza MC; Fontes CF; Frugulhetti IC; Bou-Habib DC
    Curr HIV Res; 2008 May; 6(3):209-17. PubMed ID: 18473784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells.
    Hollenbaugh JA; Schader SM; Schinazi RF; Kim B
    Virology; 2015 Nov; 485():313-21. PubMed ID: 26319213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation.
    Daelemans D; Esté JA; Witvrouw M; Pannecouque C; Jonckheere H; Aquaro S; Perno CF; De Clercq E; Vandamme AM
    Mol Pharmacol; 1997 Dec; 52(6):1157-63. PubMed ID: 9396786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of NNRTIs on HIV reverse transcriptase dimerization.
    Tachedjian G; Goff SP
    Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
    Wang X; Furukawa T; Nitanda T; Okamoto M; Sugimoto Y; Akiyama S; Baba M
    Mol Pharmacol; 2003 Jan; 63(1):65-72. PubMed ID: 12488537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.
    Vinogradov SV; Poluektova LY; Makarov E; Gerson T; Senanayake MT
    Antivir Chem Chemother; 2010 Oct; 21(1):1-14. PubMed ID: 21045256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.